ABSTRACT
Introduction: Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are two common, heterogeneous, long-term illnesses which cause significant morbidity and mortality. Although they both present with breathlessness, they are treated differently. Treatment of COPD focuses mainly on relieving short-term breathlessness, whilst treatment of HF has focused on long term morbidity and mortality.
Areas covered: In this review, we aim to highlight the diagnostic challenges in distinguishing COPD from HF. We also explore the implications of their overlap, and the use of biomarkers and treatments for HF in patients with COPD to improve long-term outcomes.
Expert commentary: Cardiovascular morbidity and mortality amongst patients with COPD is substantial. Approaches which identify patients with COPD at highest cardiovascular risk may therefore be helpful. A trial targeting those patients with COPD and raised natriuretic peptide levels might be the way to test whether cardiovascular medication has anything to offer the respiratory patient.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.